BioCentury | Jan 25, 2019
Clinical News

Asterias' oligodendrocyte progenitor cell therapy improves motor function in SCI patients at 12 months

...showing that 21 of 22 patients (95%) who received 10 or 20 million cells of AST-OPC1...
...at least one motor level of improvement on at least one side of their body. AST-OPC1...
...and bathing. No patient in SCiStar had a decrease in motor function following treatment with AST-OPC1...
BioCentury | Nov 3, 2017
Financial News

Asterias raises $10.4M in registered direct offering

...company said it will use the funds to further development of its stem cell therapy AST-OPC1...
...I/IIa study to treat spinal cord injury (SCI). Asterias Biotherapeutics Inc. (NYSE-M:AST), Fremont, Calif. Elizabeth S. Eaton AST-OPC1 Asterias...
BioCentury | May 5, 2017
Clinical News

DMC recommends continuation of Ph I/IIa of AST-OPC1 for SCI

...said a DMC recommended enrollment continuation of the 10 and 20 million cell cohorts of AST-OPC1...
...2 or 10 million cells of AST-OPC1 or 2 injections of 10 million cells of AST-OPC1...
...2016 & Sept. 26, 2016 ). The company expects to report additional data this year. AST-OPC1...
BioCentury | Sep 26, 2016
Clinical News

AST-OPC1: Additional Phase I/IIa data

...with a complete cervical SCI who received a single injection of 10 million cells of AST-OPC1...
...2 or 10 million cells of AST-OPC1 or 2 injections of 10 million cells of AST-OPC1...
...in the trial (see BioCentury, Sept. 12). Asterias Biotherapeutics Inc. (NYSE-M:AST), Menlo Park, Calif. Product: AST-OPC1...
BioCentury | Sep 12, 2016
Clinical News

AST-OPC1: Phase I/IIa data

...U.S. Phase I/IIa SCiStar trial showing that a single injection of 10 million cells of AST-OPC1...
...2 or 10 million cells of AST-OPC1 or 2 injections of 10 million cells of AST-OPC1...
...days following SCI. Interim data from a cohort of patients receiving 10 million cells of AST-OPC1...
BioCentury | Sep 5, 2016
Clinical News

AST-OPC1: Phase I/IIa ongoing

...million or 10 million cells of AST-OPC1 and 2 injections of 10 million cells of AST-OPC1...
...SCiStar originally included patients with complete SCI. Asterias Biotherapeutics Inc. (NYSE-M:AST), Menlo Park, Calif. Product: AST-OPC1...
BioCentury | Apr 6, 2015
Clinical News

AST-OPC1: Phase I/IIa started

...million or 10 million cells of AST-OPC1 and 2 injections of 10 million cells of AST-OPC1...
...enrollment to up to 40 patients. Asterias Biotherapeutics Inc . (NYSE-M:AST), Menlo Park, Calif. Product: AST-OPC1...
BioCentury | Jun 2, 2014
Company News

BioTime, Sangamo, Beckman Research Institute at City of Hope, California Institute for Regenerative Medicine gene/cell therapy news

...$14.3 million grant to BioTime's Asterias Biotherapeutics Inc. subsidiary to develop oligodendrocyte progenitor cells ( AST-OPC1...
...trial with the oligodendrocyte progenitor cells. Asterias plans to start a Phase I/IIa trial of AST-OPC1...
Items per page:
1 - 8 of 8